BRAF and neoplasm: Combination therapy can be used for limiting adaptive feedback, similar to the experience with v-raf murine sarcoma viral oncogene homolog B1 (BRAF) inhibitors; this is essential to maximize the durability of response in each tumour type [32, 33].